Eisen named president of Corbett Accel-Chicago

Corbett Accel Healthcare Group, a unit of Omnicom Group, has promoted Elaine Eisen to president of its Chicago office, a position that has been vacant.
Eisen joined Corbett in 1992 as vice president, management supervisor. Prior to her new role, she was executive vice president and director of client services; a position she was promoted to in 2000. In addition to managing the operations of the Chicago office, she will continue with strategic oversight for several key clients, including Bristol-Myers Squibb and Otsuka America Pharmaceuticals.
In partnership with Bob DeBartolo, executive vice president and director of client services, she will support agency teams working with the firm's other key clients, including Alcon Laboratories, King Pharmaceuticals and Hospira.
Eisen started her career in healthcare marketing on the client side and worked with Pharmacia for 14 years. She then worked at Hamilton, Carver & Lee as vice president and account supervisor.
"Elaine Eisen's strong leadership skills have helped transform our company into one of the leading healthcare communications firms in the industry today, and one of the most admired within Omnicom," Scott Cotherman, chief executive of Corbett Accel Healthcare Group, said in a statement. "As a member of the management team, Eisen has demonstrated tireless dedication to clients, relentless support of market-moving ideas, and vigorous advancement of our unique culture."
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.